The technology encompasses a p27 polypeptide that has an amino acid substitution mutation at one or more of Y74, Y88, or Y89. Exemplary mutations are Y74E, Y74D, Y74R, Y88E, Y88D, Y89E, or Y89D. These mutant p27 polypeptides have been shown to be expressed in E. coli and form active Cdk4/CycD/p27 Cdk6/CycD/p27 kinase complexes in vitro.
Cyclin-Dependent Kinases (Cdk) 4 and 6 promote cell proliferation through their kinase activity. The active cellular form of the Cdk 4 or 6 enzyme forms a complex with both cyclin D (CycD) and p27 in vivo. Current therapeutics that target Cdk4 or 6 were generated in a complex that lacked p27 because of difficulties in expressing a recombinant form of p27. This technology describes a recombinantly produced engineered form of p27 that forms stable complexes with Cdk4/6 and CycD in vitro.
First-ever active in vitro expressed Cdk4/CycD/p27 and Cdk6/CycD/p27 complex
Screening for inhibitors of Cdk4/6 trimeric complexes
Name: Jeff Jackson
Phone: (831) 459-3976